RU2013155903A - Композиции, способы и устройства для респираторной доставки двух или более активных средств - Google Patents
Композиции, способы и устройства для респираторной доставки двух или более активных средств Download PDFInfo
- Publication number
- RU2013155903A RU2013155903A RU2013155903/15A RU2013155903A RU2013155903A RU 2013155903 A RU2013155903 A RU 2013155903A RU 2013155903/15 A RU2013155903/15 A RU 2013155903/15A RU 2013155903 A RU2013155903 A RU 2013155903A RU 2013155903 A RU2013155903 A RU 2013155903A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- respirable
- glycopyrrolate
- formoterol
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 12
- 230000000241 respiratory effect Effects 0.000 title claims abstract 11
- 238000000034 method Methods 0.000 title claims 53
- 150000003839 salts Chemical class 0.000 claims abstract 103
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 claims abstract 55
- 229940015042 glycopyrrolate Drugs 0.000 claims abstract 51
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims abstract 49
- 229960002848 formoterol Drugs 0.000 claims abstract 49
- 208000019693 Lung disease Diseases 0.000 claims abstract 43
- 239000003814 drug Substances 0.000 claims abstract 17
- 238000004519 manufacturing process Methods 0.000 claims abstract 8
- 230000003434 inspiratory effect Effects 0.000 claims abstract 3
- 239000002245 particle Substances 0.000 claims 59
- 239000013543 active substance Substances 0.000 claims 56
- 239000000725 suspension Substances 0.000 claims 53
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 12
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 12
- 201000003883 Cystic fibrosis Diseases 0.000 claims 12
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 12
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims 12
- 238000002360 preparation method Methods 0.000 claims 12
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 9
- 150000002222 fluorine compounds Chemical group 0.000 claims 9
- 239000000463 material Substances 0.000 claims 9
- 229940071648 metered dose inhaler Drugs 0.000 claims 9
- 150000003904 phospholipids Chemical class 0.000 claims 9
- OBRNDARFFFHCGE-PERKLWIXSA-N (S,S)-formoterol fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 OBRNDARFFFHCGE-PERKLWIXSA-N 0.000 claims 6
- SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 claims 6
- PYHXGXCGESYPCW-UHFFFAOYSA-M 2,2-diphenylacetate Chemical compound C=1C=CC=CC=1C(C(=O)[O-])C1=CC=CC=C1 PYHXGXCGESYPCW-UHFFFAOYSA-M 0.000 claims 6
- ALKYHXVLJMQRLQ-UHFFFAOYSA-N 3-Hydroxy-2-naphthoate Chemical class C1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-N 0.000 claims 6
- ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 claims 6
- XRHGYUZYPHTUJZ-UHFFFAOYSA-M 4-chlorobenzoate Chemical compound [O-]C(=O)C1=CC=C(Cl)C=C1 XRHGYUZYPHTUJZ-UHFFFAOYSA-M 0.000 claims 6
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 claims 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 6
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 6
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims 6
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims 6
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 6
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 6
- 208000000059 Dyspnea Diseases 0.000 claims 6
- 206010013975 Dyspnoeas Diseases 0.000 claims 6
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims 6
- 206010020751 Hypersensitivity Diseases 0.000 claims 6
- 206010061218 Inflammation Diseases 0.000 claims 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 6
- 229910002651 NO3 Inorganic materials 0.000 claims 6
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 6
- 229910019142 PO4 Inorganic materials 0.000 claims 6
- 206010035664 Pneumonia Diseases 0.000 claims 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims 6
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 6
- 206010039085 Rhinitis allergic Diseases 0.000 claims 6
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 6
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims 6
- 201000010105 allergic rhinitis Diseases 0.000 claims 6
- 230000007815 allergy Effects 0.000 claims 6
- 208000006673 asthma Diseases 0.000 claims 6
- 229940001468 citrate Drugs 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 6
- 229960000193 formoterol fumarate Drugs 0.000 claims 6
- 230000004054 inflammatory process Effects 0.000 claims 6
- 229940001447 lactate Drugs 0.000 claims 6
- 229940049920 malate Drugs 0.000 claims 6
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 6
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 6
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 6
- 239000010452 phosphate Substances 0.000 claims 6
- 239000003380 propellant Substances 0.000 claims 6
- 230000002685 pulmonary effect Effects 0.000 claims 6
- 208000002815 pulmonary hypertension Diseases 0.000 claims 6
- 230000008695 pulmonary vasoconstriction Effects 0.000 claims 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims 6
- 208000013220 shortness of breath Diseases 0.000 claims 6
- 201000009890 sinusitis Diseases 0.000 claims 6
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 6
- 229940095064 tartrate Drugs 0.000 claims 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 6
- -1 triphenyl acetate Chemical compound 0.000 claims 6
- 235000013365 dairy product Nutrition 0.000 claims 5
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims 3
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims 3
- 229940077388 benzenesulfonate Drugs 0.000 claims 3
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims 3
- 230000001747 exhibiting effect Effects 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000008267 milk Substances 0.000 claims 1
- 235000013336 milk Nutrition 0.000 claims 1
- 210000004080 milk Anatomy 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L9/00—Disinfection, sterilisation or deodorisation of air
- A61L9/015—Disinfection, sterilisation or deodorisation of air using gaseous or vaporous substances, e.g. ozone
- A61L9/02—Disinfection, sterilisation or deodorisation of air using gaseous or vaporous substances, e.g. ozone using substances evaporated in the air by heating or combustion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2011/036868 WO2012158166A1 (en) | 2011-05-17 | 2011-05-17 | Compositions, methods & systems for respiratory delivery of two or more active agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013155903A true RU2013155903A (ru) | 2015-06-27 |
Family
ID=47177229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013155903/15A RU2013155903A (ru) | 2011-05-17 | 2011-05-17 | Композиции, способы и устройства для респираторной доставки двух или более активных средств |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP2709447A4 (es) |
| JP (1) | JP2014518871A (es) |
| KR (1) | KR20140032404A (es) |
| CN (1) | CN103687483A (es) |
| AU (1) | AU2011368334A1 (es) |
| BR (1) | BR112013029507A2 (es) |
| CA (1) | CA2835927A1 (es) |
| EA (1) | EA201490991A1 (es) |
| IL (1) | IL229260A0 (es) |
| MX (1) | MX2013013440A (es) |
| PH (1) | PH12013502270A1 (es) |
| RU (1) | RU2013155903A (es) |
| SG (1) | SG194896A1 (es) |
| WO (1) | WO2012158166A1 (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120015334A (ko) | 2009-05-29 | 2012-02-21 | 펄 테라퓨틱스 인코포레이티드 | 활성제의 호흡기 전달용 조성물, 및 연관된 방법 및 시스템 |
| US8815258B2 (en) | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
| EA201591415A1 (ru) | 2013-01-31 | 2016-01-29 | Просоникс Лимитед | Фармацевтические композиции, включающие многокомпонентные кристаллические частицы, подходящие для применения в ингаляционной терапии |
| EP2968152B2 (en) | 2013-03-15 | 2022-06-22 | Pearl Therapeutics, Inc. | Methods and systems for conditioning of particulate crystalline materials |
| MX2015016058A (es) * | 2013-05-22 | 2016-12-20 | Pearl Therapeutics Inc | Composiciones, metodos y sistemas para el suministro por via respiratoria de tres o mas agentes activos. |
| SI3089735T1 (sl) | 2013-12-30 | 2018-10-30 | Chiesi Farmaceutici S.P.A. | Sestavek stabilne aerosolne raztopine pod tlakom, ki vsebuje glikopironijev bromid in formoterol |
| NO3096737T3 (es) * | 2013-12-30 | 2018-09-01 | ||
| MA50680A (fr) | 2014-09-09 | 2020-08-05 | Vectura Ltd | Formulation comprenant glycopyrrolate, procédé et appareil |
| WO2016170518A1 (en) | 2015-04-24 | 2016-10-27 | Glenmark Specialty S.A. | Pharmaceutical compositions comprising arformoterol and glycopyrronium |
| JP6940416B2 (ja) * | 2015-05-01 | 2021-09-29 | ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System | 多剤脆性マトリックス組成物 |
| CN105125542A (zh) * | 2015-08-23 | 2015-12-09 | 杭州紫金医药科技有限公司 | 含噻托溴铵和福莫特罗的药物组合物及其用途和制剂 |
| CN106880637B (zh) * | 2015-12-15 | 2021-01-29 | 天津金耀集团有限公司 | 一种环索奈德福莫特罗噻托溴铵复方干粉吸入剂组合物 |
| CN106880636A (zh) * | 2015-12-15 | 2017-06-23 | 天津金耀集团有限公司 | 一种环索奈德单方和复方干粉吸入剂组合物 |
| CN106943350A (zh) * | 2017-03-14 | 2017-07-14 | 上海现代药物制剂工程研究中心有限公司 | 含毒蕈碱受体拮抗剂和β2受体激动剂的气雾剂及制备方法 |
| WO2020100040A1 (en) * | 2018-11-12 | 2020-05-22 | 3M Innovative Properties Company | Umeclidinium and vilanterol formulation and inhaler |
| WO2021071967A1 (en) * | 2019-10-09 | 2021-04-15 | Island Breeze Systems Ca, Llc | Compositions for pulmonary delivery of cannabinoids and associated methods and systems |
| CN111467498A (zh) * | 2020-05-14 | 2020-07-31 | 王兆霖 | 药物组合物制剂 |
| TW202241410A (zh) * | 2021-01-08 | 2022-11-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | 可經由定量吸入器遞送的藥物組合物 |
| PE20240808A1 (es) * | 2021-07-09 | 2024-04-18 | Astrazeneca Pharmaceuticals Lp | Composiciones, metodos y sistemas para la administracion de farmacos en aerosol |
| CN116785239A (zh) * | 2022-03-17 | 2023-09-22 | 上海惠永药物研究有限公司 | 喷雾冷冻干燥制备微球的方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001517692A (ja) * | 1997-09-29 | 2001-10-09 | インヘール セラピューティック システムズ， インコーポレイテッド | ネブライザにおける使用のための安定化調製物 |
| US20060165606A1 (en) * | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
| GB9903759D0 (en) * | 1999-02-18 | 1999-04-14 | Novartis Ag | Organic compounds |
| SE527190C2 (sv) * | 2003-06-19 | 2006-01-17 | Microdrug Ag | Inhalatoranordning samt kombinerade doser av en beta2-agonist, ett antikolinergiskt medel och ett antiinflammatorisk steroid |
| CA2550841C (en) * | 2004-02-06 | 2012-10-02 | Meda Pharma Gmbh & Co. Kg | Novel combination of anticholinergic and .beta. mimetics for the treatment of respiratory diseases |
| KR20120015334A (ko) * | 2009-05-29 | 2012-02-21 | 펄 테라퓨틱스 인코포레이티드 | 활성제의 호흡기 전달용 조성물, 및 연관된 방법 및 시스템 |
| US8815258B2 (en) * | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
-
2011
- 2011-05-17 RU RU2013155903/15A patent/RU2013155903A/ru not_active Application Discontinuation
- 2011-05-17 PH PH1/2013/502270A patent/PH12013502270A1/en unknown
- 2011-05-17 MX MX2013013440A patent/MX2013013440A/es unknown
- 2011-05-17 JP JP2014511329A patent/JP2014518871A/ja active Pending
- 2011-05-17 SG SG2013083431A patent/SG194896A1/en unknown
- 2011-05-17 EP EP11865780.8A patent/EP2709447A4/en not_active Withdrawn
- 2011-05-17 KR KR1020137030446A patent/KR20140032404A/ko not_active Ceased
- 2011-05-17 CN CN201180072341.4A patent/CN103687483A/zh active Pending
- 2011-05-17 BR BR112013029507A patent/BR112013029507A2/pt not_active IP Right Cessation
- 2011-05-17 EA EA201490991A patent/EA201490991A1/ru unknown
- 2011-05-17 CA CA2835927A patent/CA2835927A1/en not_active Abandoned
- 2011-05-17 AU AU2011368334A patent/AU2011368334A1/en not_active Abandoned
- 2011-05-17 WO PCT/US2011/036868 patent/WO2012158166A1/en not_active Ceased
-
2013
- 2013-11-05 IL IL229260A patent/IL229260A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN103687483A (zh) | 2014-03-26 |
| IL229260A0 (en) | 2014-01-30 |
| CA2835927A1 (en) | 2012-11-22 |
| BR112013029507A2 (pt) | 2019-09-24 |
| KR20140032404A (ko) | 2014-03-14 |
| EA201490991A1 (ru) | 2014-09-30 |
| JP2014518871A (ja) | 2014-08-07 |
| SG194896A1 (en) | 2013-12-30 |
| PH12013502270A1 (en) | 2014-01-27 |
| MX2013013440A (es) | 2014-06-05 |
| WO2012158166A1 (en) | 2012-11-22 |
| EP2709447A4 (en) | 2014-10-22 |
| AU2011368334A1 (en) | 2013-11-21 |
| EP2709447A1 (en) | 2014-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013155903A (ru) | Композиции, способы и устройства для респираторной доставки двух или более активных средств | |
| RU2020102859A (ru) | Композиции для легочной доставки антагонистов мускариновых рецепторов длительного действия и агонистов b2-адренергических рецепторов длительного действия и связанные с ними способы и системы | |
| CN1822817B (zh) | 用于治疗肺性高血压的可吸入制剂及其使用方法 | |
| RU2015154720A (ru) | Композиции, способы и системы для респираторной доставки трех или более активных средств | |
| JP6827948B2 (ja) | 呼吸器疾患の治療 | |
| JP5809985B2 (ja) | ４−｛（１ｒ）−２−［（６−｛２−［（２，６−ジクロロベンジル）オキシ］エトキシ｝ヘキシル）アミノ］−１−ヒドロキシエチル｝−２−（ヒドロキシメチル）フェノールを含む医薬製剤 | |
| AU2012216890A1 (en) | Combination of glycopyrrolate and a beta2 -agonist | |
| JP6129081B2 (ja) | 頻拍を治療するためのグリコピロラートの使用 | |
| CA2496699A1 (en) | Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids | |
| CN102724974A (zh) | 毒蕈碱受体拮抗剂和β-2肾上腺素受体激动剂的组合 | |
| US20070276048A1 (en) | Unit dose formulations comprising an inhalable solution of albuterol | |
| CN101657191B (zh) | 包括福莫特罗和二丙酸倍氯米松的组合物在制备用于预防和/或治疗哮喘恶化的药物中的用途 | |
| CN119947727A (zh) | 用于增加谷值肺功能的恩塞芬汀(rpl-554) | |
| UA119774C2 (uk) | Комбінації формотеролу і будесоніду для лікування хронічної обструктивної хвороби легень (хохл) | |
| CN104955448A (zh) | 适用于吸入治疗的包含多组分结晶颗粒的药物组合物 | |
| TW201735914A (zh) | 用於治療慢性阻塞性肺疾病之醫藥組成物 | |
| US20170367971A1 (en) | Novel propellant containing preparations for tiotropium | |
| US20090163531A1 (en) | Use of Tiotropium Salts in the Treatment of Severe Persistent Asthma | |
| ES2882978T3 (es) | Uso de 3-[5-amino-4-(3-cianobenzoil)-pirazol-1-il]-N-ciclopropil-4-metilbenzamida en la prevención de exacerbaciones agudas de la enfermedad de obstrucción pulmonar crónica | |
| US20170119744A1 (en) | Pharmaceutical Composition Comprising a Beta-2-Agonist and Anticholinergic Agent | |
| EP4499099A1 (en) | Liquid formulations of indacaterol and glycopyrronium | |
| JP7280627B2 (ja) | 慢性閉塞性肺疾患の急性増悪の処置における３－［５－アミノ－４－（３－シアノベンゾイル）－ピラゾール－１－イル］－ｎ－シクロプロピル－４－メチルベンズアミドの使用 | |
| CN117838671A (zh) | 一种含维兰特罗的吸入溶液药物组合物及其制备方法 | |
| Armstrong et al. | The role of aclidinium bromide in the treatment of chronic obstructive pulmonary disease | |
| HK40058742B (zh) | 呼吸性疾病的治疗 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20160627 |